Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 10 Oct 16

Research and Markets has announced the addition of the "Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016" report to their offering.

'Venous Leg Ulcers - Pipeline Review, H2 2016'; Venous Leg Ulcers (Crural ulcer) pipeline therapeutics constitutes close to 15 molecules. which approximately 15 molecules are developed by Companies.

Furthermore, the publisher says; Venous Leg Ulcers (Crural ulcer) Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche).

The report 'Venous Leg Ulcers - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 5, 2, 4 and 1 respectively.

Key Topics Covered:

  1. Introduction
  2. Venous Leg Ulcers Overview
  3. Therapeutics Development
  4. Pipeline Products for Venous Leg Ulcers - Overview
  5. Pipeline Products for Venous Leg Ulcers - Comparative Analysis
  6. Venous Leg Ulcers - Therapeutics under Development by Companies
  7. Venous Leg Ulcers - Therapeutics under Investigation by Universities/Institutes
  8. Venous Leg Ulcers Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Venous Leg Ulcers - Products under Development by Companies
  13. Venous Leg Ulcers - Products under Investigation by Universities/Institutes
  14. Venous Leg Ulcers - Companies Involved in Therapeutics Development
  • Adocia
  • CardioVascular BioTherapeutics, Inc.
  • CytoTools AG
  • FirstString Research, Inc.
  • MacroCure Ltd.
  • MediWound Ltd.
  • NovaLead Pharma Pvt. Ltd.
  • Pergamum AB
  • RegeneRx Biopharmaceuticals, Inc.
  • Stratatech Corporation
  • Tissue Therapies Limited

For more information about this report visit http://www.researchandmarkets.com/research/n2wfwf/venous_leg_ulcers

View source version on businesswire.com: http://www.businesswire.com/news/home/20161010005652/en/

Business Wire
www.businesswire.com

Last updated on: 10/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.